AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24195627 — intervention group
Group type: EXPERIMENTAL
Intervention: High milk-calcium (CAL) meal (9 mg · kg(‐1) of body mass)
Number of subjects: 9
Study 24195627 — intervention group
Group type: COMPARATOR
Intervention: Control trial (3 mg · kg(‐1) of body mass)
Number of subjects: 9
Study 24195627 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (CAL and Control)
Number of subjects: 9
Study 21822145 — intervention group
Group type: EXPERIMENTAL
Intervention: SL65.0472‐00 (20 mg)
Number of subjects: 24
Study 21822145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21822145 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (agonist)
Number of subjects: 24
Study 17717114 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1,000 mg/day)
Number of subjects: 40
Study 17717114 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin
Number of subjects: 40
Study 17717114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15128882 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 24
Study 15128882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12162481 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow lenses (29.7% light transmission)
Number of subjects: 15
Study 12162481 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange lenses (22.9% light transmission)
Number of subjects: 15
Study 12162481 — intervention group
Group type: EXPERIMENTAL
Intervention: Red lenses (16.8% light transmission)
Number of subjects: 15
Study 12162481 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey lenses (10.3% light transmission)
Number of subjects: 15
Study 12162481 — intervention group
Group type: COMPARATOR
Intervention: No lens (control condition)
Number of subjects: 15
Study 9651688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (n = 43)
Number of subjects: 85
Study 9651688 — intervention group
Group type: COMPARATOR
Intervention: Outpatient follow-up (n = 42)
Number of subjects: 85
Study 8633188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lithium carbonate
Number of subjects: 12
Study 8633188 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lithium carbonate
Number of subjects: 12
Study 8633188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infused at a low rate of 0.005 micrograms/kg/min for 3 hours.
Number of subjects: 5
Study 2527199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infused into the brachial artery at a rate of 0.005 micrograms/dl forearm tissue/min for 30 minutes.
Number of subjects: 5
Study 2527199 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 5
Study 3259 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (specific types not mentioned)
Number of subjects: 0
Study 3259 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0
Study 3259 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 31333730 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 20
Study 31333730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28362511 — intervention group
Group type: COMPARATOR
Intervention: 45 Gy in 30# twice daily radiotherapy (control arm)
Number of subjects: 100
Study 28362511 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy in 33# once daily radiotherapy (experimental arm)
Number of subjects: 100
Study 25096893 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rapid HIV-testing
Number of subjects: 2828
Study 23041011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 73
Study 23041011 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 73
Study 21952250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v.
Number of subjects: 40
Study 21952250 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 18423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole (90‐mg bolus followed by 9‐mg/h infusion)
Number of subjects: 66
Study 18423628 — intervention group
Group type: COMPARATOR
Intervention: Oral lansoprazole (120‐mg bolus followed by 30 mg every 3 hours)
Number of subjects: 66
Study 18423628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lansoprazole
Number of subjects: 66
Study 18423628 — intervention group
Group type: COMPARATOR
Intervention: Oral lansoprazole
Number of subjects: 66
Study 16886111 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair with longitudinal incision and transverse suture on the vaginal posterior wall (study group, n=72)
Number of subjects: 146
Study 16886111 — intervention group
Group type: COMPARATOR
Intervention: Traditional repair with longitudinal incision and longitudinal suture (control group, n=74)
Number of subjects: 146
Study 15545311 — intervention group
Group type: EXPERIMENTAL
Intervention: DB (10 mg)
Number of subjects: 36
Study 15545311 — intervention group
Group type: EXPERIMENTAL
Intervention: DM (25 mg)
Number of subjects: 36
Study 15545311 — intervention group
Group type: EXPERIMENTAL
Intervention: MP (100 mg)
Number of subjects: 36
Study 15545311 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled urine pH
Number of subjects: 36
Study 11684534 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (105 mg/d)
Number of subjects: 44
Study 11684534 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iron diet (2.25 mg/d)
Number of subjects: 44
Study 9835465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape Stripping (TS)
Number of subjects: 68
Study 9835465 — intervention group
Group type: COMPARATOR
Intervention: Control (no Tape Stripping)
Number of subjects: 68
Study 7926098 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple washing
Number of subjects: 98
Study 7926098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sephadex columns
Number of subjects: 98
Study 7926098 — intervention group
Group type: COMPARATOR
Intervention: Percoll density gradient
Number of subjects: 98
Study 2509120 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for the first six postoperative weeks
Number of subjects: 176
Study 2509120 — intervention group
Group type: COMPARATOR
Intervention: No anti-inflammatory treatment (Control)
Number of subjects: 176
Study 775991 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive medication
Number of subjects: 211
Study 775991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 30562138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT)
Number of subjects: 41
Study 30562138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 28937062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 62
Study 28937062 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (Control)
Number of subjects: 62
Study 26307614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care (NLC)
Number of subjects: 349
Study 26307614 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led outpatient care (RLC)
Number of subjects: 349
Study 23698496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + bupivacaine 0.5%
Number of subjects: 126
Study 23698496 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 mL + bupivacaine 0.5%
Number of subjects: 126
Study 23698496 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Dexamethasone and Control)
Number of subjects: 126
Study 20673246 — intervention group
Group type: COMPARATOR
Intervention: Trigger point injection with 0.25% bupivacaine twice weekly, cyclobenzaprine chlorhydrate 10 mg/day, sodium dipyrone 500 mg every 8 hours
Number of subjects: 30
Study 20673246 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical and trigger point acupuncture twice weekly
Number of subjects: 30
Study 19267264 — intervention group
Group type: EXPERIMENTAL
Intervention: 3MV intervention (n = 164)
Number of subjects: 338
Study 19267264 — intervention group
Group type: COMPARATOR
Intervention: Wait-list comparison condition (n = 174)
Number of subjects: 338
Study 15919678 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily
Number of subjects: 431
Study 15919678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 15580195 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene occlusive skin wrapping
Number of subjects: 55
Study 15580195 — intervention group
Group type: COMPARATOR
Intervention: Conventional drying (control)
Number of subjects: 55
Study 11726831 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (2 mg/kg on POD 0 and 14), tacrolimus, mycophenolate mofetil, and corticosteroids on POD 0 and 1, then discontinuation of corticosteroids.
Number of subjects: 30
Study 11726831 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, mycophenolate mofetil, and corticosteroids (standard regimen).
Number of subjects: 30
Study 11726831 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab, tacrolimus, mycophenolate mofetil, and corticosteroids (discontinued after POD 1).
Number of subjects: 30
Study 9128771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scintigraphic evaluation and assessment of femoral shortening
Number of subjects: 88
Study 9128771 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy alone
Number of subjects: 88
Study 9128771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low scintigraphic uptake with minor femoral shortening
Number of subjects: 88
Study 9128771 — intervention group
Group type: EXPERIMENTAL
Intervention: High scintigraphic uptake with minor femoral shortening
Number of subjects: 88
Study 9128771 — intervention group
Group type: EXPERIMENTAL
Intervention: High scintigraphic uptake with high degree of femoral shortening
Number of subjects: 88
Study 9128771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low scintigraphic uptake with high degree of femoral shortening
Number of subjects: 88
Study 7968434 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (30 min at 40-50% VO2max)
Number of subjects: 6
Study 7968434 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (60-min seated rest)
Number of subjects: 6
Study 7968434 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 6
Study 7968434 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 6
Study 2444309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) - 2 units daily for 3 days
Number of subjects: 202
Study 2444309 — intervention group
Group type: COMPARATOR
Intervention: Colloid control - similar volume as FFP
Number of subjects: 202
Study 2444309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 202
Study 30861099 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP)
Number of subjects: 600
Study 30861099 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care
Number of subjects: 600
Study 30176632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract BNO 1055 added to standard treatment
Number of subjects: 78
Study 30176632 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive therapy (control group)
Number of subjects: 78
Study 26907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30
Study 26907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training 3:1 (CT3)
Number of subjects: 30
Study 26907840 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training 1:1 (CT1)
Number of subjects: 30
Study 26907840 — intervention group
Group type: COMPARATOR
Intervention: No Training (CON)
Number of subjects: 30
Study 24123244 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 24123244 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 24123244 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse
Number of subjects: 0
Study 22147112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY41-6551 400 mg every 12 hours (q12h)
Number of subjects: 69
Study 22147112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY41-6551 400 mg every 24 hours (q24h) with aerosol placebo
Number of subjects: 69
Study 22147112 — intervention group
Group type: COMPARATOR
Intervention: Placebo q12h
Number of subjects: 69
Study 22147112 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY41-6551
Number of subjects: 69
Study 22147112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18485453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 1158
Study 18485453 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1158
Study 17845589 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 microg plus formoterol 6 microg
Number of subjects: 228
Study 17845589 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 125 microg plus salmeterol 25 microg
Number of subjects: 228
Study 17845589 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone plus formoterol combination
Number of subjects: 228
Study 17845589 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone plus salmeterol
Number of subjects: 228
Study 15759098 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 120
Study 11928028 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopic cholecystectomy (3.5-mm LC)
Number of subjects: 60
Study 11928028 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 60
Study 9808229 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg folic acid
Number of subjects: 150
Study 9808229 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg folic acid + 6 microg vitamin B-12
Number of subjects: 150
Study 9808229 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg folic acid + 400 microg vitamin B-12
Number of subjects: 150
Study 9808229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 7649706 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (120 min/wk at 75% VO2max)
Number of subjects: 20
Study 2655829 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilized allograft (LA)
Number of subjects: 48
Study 2655829 — intervention group
Group type: COMPARATOR
Intervention: exposure treatment (EP)
Number of subjects: 48
Study 772759 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (therapeutic doses)
Number of subjects: 67
Study 772759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (therapeutic doses)
Number of subjects: 67
Study 772759 — intervention group
Group type: COMPARATOR
Intervention: None (baseline comparison)
Number of subjects: 67
Study 772759 — intervention group
Group type: COMPARATOR
Intervention: None (pre-pubertal comparison)
Number of subjects: 67
Study 772759 — intervention group
Group type: COMPARATOR
Intervention: None (age group comparison)
Number of subjects: 67
Study 31833621 — intervention group
Group type: EXPERIMENTAL
Intervention: Codonopsis lanceolata (CL) extract
Number of subjects: 80
Study 31833621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 80
Study 31265139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education program provided in the hospital
Number of subjects: 390
Study 31265139 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 390
Study 28092106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at the EX-HN3 (Yintang) point
Number of subjects: 128
Study 28092106 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 128
Study 25651494 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved trehalose 30 mg/mL and sodium hyaluronate 1.5 mg/mL (TH‐SH, Thealoz Duo)
Number of subjects: 60
Study 25651494 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpreserved sodium hyaluronate, 0.15% (HA, Hyabak)
Number of subjects: 60
Study 25651494 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride, 0.9% (NaCl, Hydrabak)
Number of subjects: 60
Study 24995488 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength + stretch exercise program
Number of subjects: 57
Study 24995488 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch alone exercise program
Number of subjects: 57
Study 24995488 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 57
Study 21992924 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine with atazanavir/ritonavir (ATV/r)
Number of subjects: 91
Study 21992924 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine with efavirenz (EFV)
Number of subjects: 91
Study 19391056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser therapy every 2 weeks
Number of subjects: 45
Study 19391056 — intervention group
Group type: COMPARATOR
Intervention: Topical preparations
Number of subjects: 45
Study 19391056 — intervention group
Group type: COMPARATOR
Intervention: Chemical peeling using trichloroacetic acid 25%
Number of subjects: 45
Study 17720659 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r 400/300 mg bid
Number of subjects: 36
Study 17720659 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r 667/167 mg bid
Number of subjects: 36
Study 17720659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 36
Study 15180728 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscope (E, diameter 9.8 mm)
Number of subjects: 160
Study 15180728 — intervention group
Group type: COMPARATOR
Intervention: Standard sigmoidoscope (S, diameter 13.3 mm)
Number of subjects: 160
Study 15811145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (800 microg nocte)
Number of subjects: 11
Study 15811145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10575912 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole with amoxicillin and clarithromycin
Number of subjects: 224
Study 10575912 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole with clarithromycin and metronidazole
Number of subjects: 224
Study 10575912 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth with amoxicillin and metronidazole
Number of subjects: 224
Study 10575912 — intervention group
Group type: COMPARATOR
Intervention: Control endoscopy
Number of subjects: 224
Study 8908921 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI)
Number of subjects: 50
Study 8908921 — intervention group
Group type: COMPARATOR
Intervention: Light-cured resin sealant
Number of subjects: 50
Study 1914413 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen SR
Number of subjects: 17
Study 1914413 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium SR
Number of subjects: 17
Study 6614325 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg intravenously before operation)
Number of subjects: 209
Study 6614325 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin (5 g intravenously before operation)
Number of subjects: 209
Study 30741832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 84
Study 30741832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol 0.5 mg/kg and lidocaine 1.5 mg/kg
Number of subjects: 84
Study 30741832 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline only)
Number of subjects: 84
Study 30800079 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive 18-month intervention incorporating health behavior coaching and care coordination/care management.
Number of subjects: 0
Study 30800079 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior coaching and care coordination/care management delivered by a health coach and nurse.
Number of subjects: 0
Study 27093939 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor
Number of subjects: 3350
Study 27093939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3350
Study 24423410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program‐derived print/telephone lifestyle intervention (13 telephonic sessions tailored to pregnant/postpartum women)
Number of subjects: 2320
Study 24423410 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices (two pages of printed lifestyle recommendations sent to postpartum women via mail)
Number of subjects: 2320
Study 24423410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program‐derived print/telephone lifestyle intervention
Number of subjects: 2320
Study 24423410 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices
Number of subjects: 2320
Study 23028897 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg selenium/d
Number of subjects: 501
Study 23028897 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg selenium/d
Number of subjects: 501
Study 23028897 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 µg selenium/d
Number of subjects: 501
Study 23028897 — intervention group
Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 501
Study 20137761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg b.i.d for 7 days along with standard doses of aspirin and clopidogrel
Number of subjects: 40
Study 20137761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18608093 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg) - Creatine (10 g) twice daily for six months
Number of subjects: 60
Study 18608093 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg) - Creatine (10 g) twice daily for six months
Number of subjects: 60
Study 18608093 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 60